Corvus Pharmaceuticals (NASDAQ: [[ticker:CRVS]]) has appointed Mehrdad Mobasher to serve as vice president and chief medical officer. Mobasher comes to Burlingame, CA-based Corvus after eight years at Genentech, where he was most recently group medical director. Lead Corvus drug candidate CPI-444 is in early-stage clinical testing in various solid tumors. Corvus is developing that drug in a partnership with Genentech that began in 2015.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
